Skip to main content

GlaxoSmithKline-gsk-logo

Patients with active systemic lupus erythematosus (SLE) were able to control their disease with Benlysta (belimumab) plus standard of care (prednisone), pharmaceutical giant GSK said in announcing the results from a 10-year continuation study.

GSK presented the study’s results at the Annual European Congress of Rheumatology (EULAR 2017), held June 14-17 in Madrid.

{iframe}https://lupusnewstoday.com/2017/06/19/lupus-therapy-benlysta-achieves-sustained-disease-control-concludes-10-year-gsk-study/{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.